|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics. CA Cancer J Clin. 59:225–249. 2009.
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Walsh JM and Terdiman JP: Colorectal
cancer screening: scientific review. JAMA. 289:1288–1296. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Visone R and Croce CM: MiRNAs and cancer.
Am J Pathol. 174:1131–1138. 2009. View Article : Google Scholar
|
|
6
|
Slaby O, Svoboda M, Michalek J and Vyzula
R: MicroRNAs in colorectal cancer: translation of molecular biology
into clinical application. Mol Cancer. 8:1022009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chim SS, Shing TK, Hung EC, Leung TY, Lau
TK, Chiu RW and Lo YM: Detection and characterization of placental
microRNAs in maternal plasma. Clin Chem. 54:482–490. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lawrie CH, Gal S, Dunlop HM, Pushkaran B,
Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J,
Wainscoat JS, Hatton CS and Harris AL: Detection of elevated levels
of tumour-associated microRNAs in serum of patients with diffuse
large B-cell lymphoma. Br J Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP
and Wei WI: Mature miR-184 as potential oncogenic microRNA of
squamous cell carcinoma of tongue. Clin Cancer Res. 14:2588–2592.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kosaka N, Iguchi H and Ochiya T:
Circulating microRNA in body fluid: a new potential biomarker for
cancer diagnosis and prognosis. Cancer Sci. 101:2087–2092. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Calin CA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar
|
|
12
|
Calin GA, Ferracin M, Cimmino A, Di Leva
G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M,
Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C,
Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M and
Croce CM: A microRNA signature associated with prognosis and
progression in chronic lymphocytic leukemia. N Engl J Med.
353:1793–1801. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schetter AJ, Leung SY, Sohn JJ, Zanetti
KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu
CG, Calin GA, Croce CM and Harris CC: MicroRNA expression profiles
associated with prognosis and therapeutic outcome in colon
adenocarcinoma. JAMA. 299:425–436. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ng EK, Chong WW, Jin H, Lam EK, Shin VY,
Yu J, Poon TC, Ng SS and Sung JJ: Differential expression of
microRNAs in plasma of patients with colorectal cancer: a potential
marker for colorectal cancer screening. Gut. 58:1375–1381. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang Z, Huang D, Ni S, Peng Z, Sheng W
and Du X: Plasma microRNAs are promising novel biomarkers for early
detection of colorectal cancer. Int J Cancer. 127:118–126. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng H, Zhang L, Cogdell DE, Zheng H,
Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR and Zhang W:
Circulating plasma MiR-141 is a novel biomarker for metastatic
colon cancer and predicts poor prognosis. PLoS One. 6:e177452011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang LG and Gu J: Serum microRNA-29a is a
promising novel marker for early detection of colorectal liver
metastasis. Cancer Epidemiol. 36:e61–e67. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Asangani IA, Rasheed SA, Nikolova DA,
Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21 (miR-21)
post-transcriptionally downregulates tumor suppressor Pdcd4 and
stimulates invasion, intravasation and metastasis in colorectal
cancer. Oncogene. 27:2128–2136. 2008. View Article : Google Scholar
|
|
19
|
Wang B and Zhang Q: The expression and
clinical significance of circulating microRNA-21 in serum of five
solid tumors. J Cancer Res Clin Oncol. 138:1659–1666. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kanaan Z, Rai SN, Eichenberger MR, Roberts
H, Keskey B, Pan J and Galandiuk S: Plasma miR-21: a potential
diagnostic marker of colorectal cancer. Ann Surg. 256:544–551.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye
S, Ling S, Jiang L, Tian Y and Lin TY: Circulating miR-221 directly
amplified from plasma is a potential diagnostic and prognostic
marker of colorectal cancer and is correlated with p53 expression.
J Gastroenterol Hepatol. 25:1674–1680. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Q, Huang Z, Ni S, Xiao X, Xu Q, Wang
L, Huang D, Tan C, Sheng W and Du X: Plasma miR-601 and miR-760 are
novel biomarkers for the early detection of colorectal cancer. PLoS
One. 7:e443982012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fang Y, Xue JL, Shen Q, Chen J and Tian L:
MicroRNA-7 inhibits tumor growth and metastasis by targeting the
phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma.
Hepatology. 55:1852–1862. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li X, Zhang Y, Zhang H, Liu X, Gong T, Li
M, Sun L, Ji G, Shi Y, Han Z, Han S, Nie Y, Chen X, Zhao Q, Ding J,
Wu K and Daiming F: miRNA-223 promotes gastric cancer invasion and
metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res.
9:824–833. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Skog J, Würdinger T, van Rijn S, Meijer
DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky
AM and Breakefield XO: Glioblastoma microvesicles transport RNA and
proteins that promote tumour growth and provide diagnostic
biomarkers. Nat Cell Biol. 10:1470–1476. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wolfers J, Lozier A, Raposo G, Regnault A,
Théry C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T,
Angevin E, Amigorena S and Zitvogel L: Tumor-derived exosomes are a
source of shared tumor rejection antigens for CTL cross-priming.
Nat Med. 7:297–303. 2001.PubMed/NCBI
|
|
27
|
Kosaka N, Iguchi H, Yoshioka Y, Takeshita
F, Matsuki Y and Ochiya T: Secretory mechanisms and intercellular
transfer of microRNAs in living cells. J Biol Chem.
285:17442–17452. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zernecke A, Bidzhekov K, Noels H,
Shagdarsuren E, Gan L, Denecke B, Hristov M, Köppel T, Jahantigh
MN, Lutgens E, Wang S, Olson EN, Schober A and Weber C: Delivery of
microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular
protection. Sci Signal. 2:ra812009.PubMed/NCBI
|
|
29
|
Miyanishi M, Tada K, Koike M, Uchiyama Y,
Kitamura T and Nagata S: Identification of Tim4 as a
phosphatidylserine receptor. Nature. 450:435–439. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lieberman DA: Clinical practice. Screening
for colorectal cancer. N Engl J Med. 361:1179–1187. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Graser A, Stieber P, Nagel D, Schäfer C,
Horst D, Becker CR, Nikolaou K, Lottes A, Geisbüsch S, Kramer H,
Wagner AC, Diepolder H, Schirra J, Roth HJ, Seidel D, Göke B,
Reiser MF and Kolligs FT: Comparison of CT colonography,
colonoscopy, sigmoidoscopy and faecal occult blood tests for the
detection of advanced adenoma in an average risk population. Gut.
58:241–248. 2009. View Article : Google Scholar
|
|
32
|
Duffy MJ, van Dalen A, Haglund C, Hansson
L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C
and Topolcan O: Tumour markers in colorectal cancer: European Group
on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer.
43:1348–1360. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Spratlin JL, Hui D, Hanson J, Butts C and
Au HJ: Community compliance with carcinoembryonic antigen:
follow-up of patients with colorectal cancer. Clin Colorectal
Cancer. 7:118–125. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eleftheriadis N, Papaloukas C and
Pistevou-Gompaki K: Diagnostic value of serum tumor markers in
asymptomatic individuals. J BUON. 14:707–710. 2009.PubMed/NCBI
|
|
35
|
Amayo AA and Kuria JG: Clinical
application of tumour markers: a review. East Afr Med J.
86:S76–S83. 2009.PubMed/NCBI
|
|
36
|
Ahmed FE, Vos PW, Jeffries C, Wiley JE,
Weidner DA, Mota H, Bonnerup C, Sibata C and Allison RR:
Differences in mRNA and microRNA microarray expression profiles in
human colon adenocarcinoma HT-29 cells treated with either
intensity-modulated radiation therapy (IMRT), or conventional
radiation therapy (RT). Cancer Genomics Proteomics. 6:109–127.
2009.
|
|
37
|
Sassen S, Miska EA and Caldas C: MicroRNA:
implications for cancer. Virchows Arch. 452:1–10. 2008. View Article : Google Scholar
|
|
38
|
Brase JC, Wuttig D, Kuner R and Sültmann
H: Serum microRNAs as non-invasive biomarkers for cancer. Mol
Cancer. 9:3062010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Luo X, Burwinkel B, Tao S and Brenner H:
MicroRNA signatures: novel biomarker for colorectal cancer? Cancer
Epidemiol Biomarkers Prev. 20:1272–1286. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu WK, Law PT, Lee CW, Cho CH, Fan D, Wu
K, Yu J and Sung JJ: MicroRNA in colorectal cancer: from benchtop
to bedside. Carcinogenesis. 32:247–253. 2011. View Article : Google Scholar : PubMed/NCBI
|
